Video
Author(s):
Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.
Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.
There is very good long-term safety data for patients who are appropriately selected for active surveillance, says Choyke.
The patients who benefit from active surveillance have very low-risk cancer with a negative MRI.